News articles about Insmed (NASDAQ:INSM) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insmed earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.8900694634041 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Brokerages Anticipate Insmed Incorporated (INSM) Will Announce Earnings of -$1.05 Per Share (americanbankingnews.com)
- Insmed Incorporated (INSM) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Is Insmed Incorporated (NasdaqGS:INSM)’s Proft Growth of 0.35738 Enough For Investors? (baycityobserver.com)
- Insmed Incorporated (INSM): Most Recent Update (thenewsbloom.org)
- Day of Reckoning? Share update on Insmed Incorporated (NasdaqGS:INSM) as PCF Moves to -7.942849 (vassarnews.com)
A number of research firms recently weighed in on INSM. BidaskClub downgraded Insmed from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. ValuEngine downgraded Insmed from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research upgraded Insmed from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Wednesday, July 4th. HC Wainwright restated a “buy” rating and issued a $43.00 price target on shares of Insmed in a research note on Friday, August 3rd. Finally, Goldman Sachs Group began coverage on Insmed in a research note on Monday, July 23rd. They issued a “neutral” rating and a $32.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $39.00.
Shares of Insmed stock traded down $0.06 during trading on Thursday, reaching $20.33. The company’s stock had a trading volume of 11,266 shares, compared to its average volume of 790,264. The company has a debt-to-equity ratio of 0.83, a current ratio of 14.14 and a quick ratio of 14.14. The company has a market cap of $1.54 billion, a PE ratio of -7.03 and a beta of 1.29. Insmed has a 12-month low of $19.15 and a 12-month high of $33.94.
Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.00) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.08) by $0.08. equities research analysts anticipate that Insmed will post -4.06 EPS for the current fiscal year.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Featured Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.